Pilot Study – Use of [68Ga] gallium-labelled Prostate Specific Membrane Antigen (PSMA) Positron Emission Tomography (PET) for the Characterisation of Metastatic Lesions in Patients with Renal Cell Carcinoma
Not Applicable
Completed
- Conditions
- Kidney cancerCancer - Kidney
- Registration Number
- ACTRN12615000854538
- Lead Sponsor
- Dr Simon Wood
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 10
Inclusion Criteria
1. Patients with renal mass larger than 2cm
2. Indeterminant or likely metastatic lesions on staging CT scan
3. No known problems with peripheral intravenous or central line access
4. Able to undergo study imaging within 6 weeks of diagnosis
5. Able to provide informed signed consent
Exclusion Criteria
1. Age under 18 years
2. Administered radioisotope within 5 physical half-lives prior to PSMA PET
3. Unable to lie flat during or unable to tolerate PET
4. Prior history of any other malignancy within last 2 years
5. Contraindication to PET scan or 68 Ga PSMA PET ligand
6. Claustrophobia not manageable by oral sedatives. i.e. Temazepam.
7. Renal impairment or haemodialysis.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method